awmsg logo



budesonide (Jorveza®)


Reference No. 2656

Publication date:
17/05/2018


Appraisal information

budesonide (Jorveza®) 1 mg orodispersible tablet


Company: Dr Falk Pharma UK Ltd
BNF category: Gastro-intestinal system
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 20/04/2018

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, budesonide (Jorveza®) cannot be endorsed for use within NHS Wales for the treatment of eosinophilic oesophagitis in adults (older than 18 years of age).
Statement of Advice (SOA)
Download